Selpercatinib previously received accelerated approval for patients aged 12 years and older in 2020 and was extended to younger patients in May 2024, according to a news release from the agency.
The approval was based on the Libretto-531 study, which showed significant efficacy in adults and adolescents. This was a randomized trial, with patients receiving selpercatinib showing superior progression-free survival compared to those treated with cabozantinib or vandetanib.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
